Join
Live feed
·
PRReleasevia Quantisnow
Jasper Therapeutics Inc. logo

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

ByQuantisnow·Wall Street's wire, on your screen.
JSPR· Jasper Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JSPR (Jasper Therapeutics Inc.) and more on Quantisnow.